Peptide Database

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that extends its half-life. It was developed to increase GH and IGF-1 secretion while maintaining the natural pulsatile release pattern. Research focuses on its effects on body composition, recovery, and sleep quality.

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with 83 amino acids (compared to 70 in native IGF-1). The modifications include an arginine instead of glutamic acid at position 3 and a 13 amino acid extension at the N-terminus, resulting in reduced IGF binding protein affinity and extended half-life.

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It is considered one of the cleanest GH-releasing peptides due to its selective action on GH release without significantly affecting cortisol, prolactin, or other hormones. Research focuses on GH optimization, body composition, and recovery.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a mitochondrial-derived peptide consisting of 16 amino acids. It was discovered in 2015 and has been described as an exercise mimetic due to its effects on metabolic regulation, insulin sensitivity, and physical performance.

TB-500 is a synthetic version of a region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide present in virtually all human cells. Thymosin Beta-4 plays a crucial role in tissue repair, cell migration, and blood vessel formation. TB-500 research focuses on wound healing, anti-inflammatory properties, and tissue regeneration.

Tesamorelin (brand name Egrifta®) is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates the pituitary gland to produce growth hormone.